{"id":"W2057093576","doi":"10.1016/j.pain.2013.05.051","title":"Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain","year":2013,"lang":"en","type":"article","venue":"Pain","topic":"Osteoarthritis Treatment and Mechanisms","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Placebo; Osteoarthritis; Analgesic; Brief Pain Inventory; Adverse effect; Anesthesia; Chronic pain; Internal medicine; Randomized controlled trial; Physical therapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00151118,0.000437516,0.001235095,0.0001626209,0.0002349384,0.0004108566,0.0003373507,0.0006619315,0.001493479],"category_scores_gemma":[0.001456269,0.0001986661,0.0009684626,0.0001674075,0.0004454933,0.0004944375,0.0002033372,0.001023378,0.0002586448],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003013314,"about_ca_system_score_gemma":0.000314948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003786962,"about_ca_topic_score_gemma":0.001186348,"domain_scores_codex":[0.9993754,0.0003008174,0.00006741595,0.00005462386,0.0001188153,0.00008301009],"domain_scores_gemma":[0.9992476,0.0002605951,0.0002679375,0.00003033446,0.00004505146,0.000148621],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5395621,0.02171724,0.02568443,0.001712484,0.00156778,0.0003647522,0.0003315194,0.001544153,0.0617744,0.000148806,0.00134847,0.3442439],"study_design_scores_gemma":[0.1815942,0.711542,0.0941719,0.0001269397,0.001110255,0.000909296,0.0001518874,0.001549334,0.006534518,0.0001526562,0.002113311,0.00004370425],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927871,0.005891454,0.0001729777,0.0001590101,0.00003757644,0.0002293356,0.0001321013,0.00001470992,0.000575637],"genre_scores_gemma":[0.9968132,0.001945079,0.000401873,0.0001715794,0.00008359026,0.0001393965,0.0001472393,0.000002396721,0.0002957022],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00151118,"threshold_uncertainty_score":0.007992029,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009762249642721649,"score_gpt":0.2375900371841291,"score_spread":0.2278277875414075,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}